Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

Growth is forecast to continue in the 23-25% range in eFY25. Tempus is expecting to close the Ambry acquisition in Q1 2025. The deal will be accretive to Tempus' adjusted EBITDA margin while ...

Ambry Genetics drives innovation in diagnostics by launching cutting-edge genetic tests and technologies. Its broad collaborations, novel research projects, and networks for data sharing ...